Given its central role in ligand-mediated activation along with its well-characterised structure, the LBD has historically been a primary focus for drug discovery in prostate cancer, as its inhibition effectively suppresses AR-driven transcription and tumour progression [10]. Here, AR is linked to neoplasm.